Please assess the completion status of the following clinical trial:

Trial Title: Moxonidine for Prevention of Post-ablation AFib Recurrences

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertensive patients with paroxysmal atrial fibrillation.~* At least two documented episodes within the last 12 months (either self-terminating within 7 days or cardioverted, medically or electrically, in less than 48 hours).~* At least one episode should have been documented under treatment with a class Ic or III antiarrhythmic drug.~Exclusion Criteria:~1. age \<25 or \>80 years~2. presence of atrial thrombus~3. left atrial volume index \>55 ml/m2~4. hypersensitivity to moxonidine~5. sick sinus syndrome or sino-atrial block~6. 2nd or 3rd degree atrioventricular block~7. bradycardia (below 50 beats/minute at rest)~8. estimated glomerular filtration rate \<40 ml/min/1.73 m2~9. history of angioneurotic oedema~10. heart failure symptoms OR impaired left ventricular function (EF \<40%), even if asymptomatic~11. stable or unstable angina pectoris~12. intermittent claudication or known peripheral artery disease~13. Parkinson's disease~14. epileptic disorders~15. glaucoma~16. history of depression~17. pregnancy or lactation~18. inability or unwillingness to adhere to standard treatment or to provide consent.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal \<= 140/90).
- Moxonidine group (Type: ACTIVE_COMPARATOR): Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal \<= 140/90).

Based on this trial design, predict the completion outcome and termination type (if applicable).